Evidence map›Paper›PMID 35615790›Full record

ArticleThe Journal of international medical research2022

Differential malondialdehyde (MDA) detection in plasma samples of patients with major depressive disorder (MDD): A potential biomarker.

Miguel A Alvarez-Mon, Miguel A Ortega, Cielo García-Montero, Oscar Fraile-Martinez, Guillermo Lahera, Jorge Monserrat, Ana M Gomez-Lahoz, Patricio Molero, Luis Gutierrez-Rojas, Roberto Rodriguez-Jimenez and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06158152 (A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06158152 narecruitingnot on this mapstarted 2024, after this paper: background citation

A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.

TypeinterventionalSponsorIndustrial Farmacéutica Cantabria, S.A.Ran2024 to 2026Enrolled48ConditionsMetabolic SyndromeArmsAM3 + Probiotic, Placebo, AM3
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Oxidative and Nitrosative Stress in Atopic Dermatitis and Depression: Similarities in Biomarkers and Pathophysiological Mechanisms.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Miguel A Alvarez-MonDepartment of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain.
Miguel A OrtegaDepartment of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain.ORCID https://orcid.org/0000-0003-2588-1708
Cielo García-MonteroDepartment of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain.
Oscar Fraile-MartinezDepartment of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain.
Guillermo LaheraDepartment of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain.
Jorge MonserratDepartment of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain.
Ana M Gomez-LahozDepartment of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain.
Patricio MoleroDepartment of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain.ORCID https://orcid.org/0000-0002-9287-9635
Luis Gutierrez-RojasDepartment of Psychiatry, Faculty of Medicine, University of Granada, Granada, Spain.
Roberto Rodriguez-JimenezDepartment of Legal Medicine and Psychiatry, Complutense University, Madrid, Spain.
Javier QuinteroDepartment of Psychiatry and Mental Health, Hospital Universitario Infanta Leonor, Madrid, Spain.
Melchor Alvarez-MonDepartment of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain.
Universidad de Alcalá · ESUniversidad Complutense de Madrid · ESClinica Universidad de Navarra · ESUniversidad de Granada · ES

Funding

NIMHD NIH HHS L60 MD003804
6 · The paper itself

Abstract

objectiveTo measure plasma levels of malondialdehyde (MDA), a marker of oxidative stress (OS), in patients with major depressive disorder (MDD) compared with healthy control (HC) subjects in order to determine if it is a possible biomarker of depression.

methodsThis prospective cross-sectional study enrolled patients with MDD and HC subjects. The plasma levels of MDA were measured using a commercially-available colorimetric assay.

resultsA total of 30 patients with MDD and 20 HC subjects with similar sex, age and body mass index distribution were enrolled in the study. Patients with MDD had significantly higher plasma levels of MDA than the HC subjects. Receiver operating characteristic curve analysis for plasma MDA levels in patients with MDD demonstrated an area under the curve of 0.9767.

conclusionThe findings of this current study provide further evidence of the role pathophysiological relevance of OS and MDA in MDD. This study provides the basis for the use of MDA as a biomarker for MDD.

Indexed as

Major Depressive DisorderBiomarkersCross-Sectional StudiesHumansMalondialdehydeProspective StudiesBiomarkersMalondialdehydeMajor depressive disorder (MDD)malondialdehyde (MDA)oxidative stressplasma biomarker

Identifiers

PMID35615790
PMCPMC9149615
OpenAlexW4281776881

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.